Average Ratings 0 Ratings
Average Ratings 0 Ratings
Description
Specialty and rare diseases often encompass patient populations that are not clearly defined, including individuals who remain undiagnosed or face misdiagnoses, along with healthcare providers who may lack knowledge about these conditions and their various manifestations, resulting in treatment pathways that are poorly understood. IPM.ai operates as an Insights-as-a-Service (IaaS) firm, dedicated to empowering leading life sciences organizations to gain deeper insights into patient care and enhance the quality of life for those affected through the development, clinical research, and commercialization of therapeutic solutions. By predicting market size, analyzing the competitive landscape, and estimating potential return on investment, companies can optimize their commercialization strategies. Additionally, the platform identifies undiagnosed and misdiagnosed individuals who could benefit from early disease interception and therapeutic measures. It employs statistical models to gauge the prevalence of specific diseases within certain patient populations at any given moment. Furthermore, IPM.ai helps pinpoint physicians who are adept at diagnosing and treating these ideal patients, while also influencing other healthcare providers to enhance overall patient outcomes. This comprehensive approach ultimately aims to bridge the gap in understanding and addressing the needs of those with rare diseases.
Description
The microbiome plays a significant role in various diseases and health issues. Discover how Kaleido is pioneering a unique method to transform the potential of the microbiome into effective patient solutions. Comprising over 30 trillion microbes, the human microbiome includes a diverse array of organisms such as bacteria, viruses, archaea, and fungi that inhabit both the exterior and interior of the human body. In recent years, there has been a remarkable surge in research focusing on the microbiome's influence on human health, linking it to conditions such as cardiovascular disease, cancer, diabetes, Parkinson’s disease, and allergies. This intricate microbial community has been likened to a "newly discovered organ," highlighting its significance. Just as many human organs command substantial investments for therapies that modify physiology, the microbiome represents a largely unexplored territory in the realm of healthcare. Addressing this frontier could unlock new therapeutic avenues and enhance overall health outcomes.
API Access
Has API
API Access
Has API
Integrations
Azure Marketplace
Pricing Details
No price information available.
Free Trial
Free Version
Pricing Details
No price information available.
Free Trial
Free Version
Deployment
Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook
Deployment
Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook
Customer Support
Business Hours
Live Rep (24/7)
Online Support
Customer Support
Business Hours
Live Rep (24/7)
Online Support
Types of Training
Training Docs
Webinars
Live Training (Online)
In Person
Types of Training
Training Docs
Webinars
Live Training (Online)
In Person
Vendor Details
Company Name
IPM.ai
Country
United States
Website
www.ipm.ai/platform
Vendor Details
Company Name
Kaleido
Founded
2015
Country
United States
Website
kaleido.com/platform/